Actuate Therapeutics, Inc. - Common stock (ACTU)

Competitors to Actuate Therapeutics, Inc. - Common stock (ACTU)

Blueprint Medicines Corporation 

Blueprint Medicines specializes in targeted therapies for genomically defined cancers, rare diseases, and cancer immunotherapy, positioning itself in similar therapeutic areas as Actuate. The company has established significant collaborations with larger pharmaceutical firms, enhancing its resource availability and market presence, which may indicate a stronger strategic advantage in rapidly advancing its drug candidates through development stages.

Iovance Biotherapeutics, Inc. 

Iovance specializes in cell therapy for cancer treatment, taking on a different yet complementary approach compared to Actuate's drug development. While Iovance employs a personalized therapeutic methodology, Actuate competes by targeting broader indications with its therapies. The unique aspect of Iovance's offerings gives it a competitive advantage in the burgeoning field of cell therapy, which is capturing significant attention in oncology.

Mirati Therapeutics, Inc.

Mirati Therapeutics is engaged in the development of innovative medicines to treat genetically defined cancers. The company's strong focus on genetic mutations has resulted in high-value drugs that address specific patient needs. While Mirati has a solid clinical pipeline, Actuate Therapeutics competes by emphasizing its unique drug candidates that target unmet medical needs, thereby carving a niche for itself despite Mirati's more robust market position.

Zymeworks Inc.

Zymeworks focuses on developing multifunctional therapeutics for the treatment of cancer and other serious diseases, competing directly with Actuate's innovative approach to drug development. Both companies leverage proprietary technology platforms for drug development, but Zymeworks benefits from a more extensive pipeline and greater financial resources, giving it a competitive edge in both research and potential market reach.